Vaxcyte, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from Needham maintained a Buy rating on the stock and has a $110.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Stringer has given his Buy rating due to a combination of factors that underscore Vaxcyte’s favorable risk‑reward profile. He highlights that the robust Phase 2 results for VAX‑31 in adults substantially reduce the clinical risk heading into the pivotal Phase 3 readout expected in the fourth quarter of 2026. He also believes Vaxcyte’s pneumococcal vaccine candidate has strong potential to be best in its class, particularly given its broad serotype coverage compared with existing options. In addition, he views the share price weakness following the late‑March 2025 selloff, and the current market valuation, as offering an appealing entry point ahead of a major clinical catalyst.
Stringer further points to Vaxcyte’s solid financial position, with approximately $2.7 billion in cash as of the end of the third quarter of 2025, which he expects will fund operations into mid‑2028 and across several important milestones. This capital buffer reduces financing risk and supports continued development across the pipeline. Finally, he anticipates that a successful Phase 3 outcome for VAX‑31 in adults could serve as a positive share-price catalyst and sustain momentum going into the Phase 2 infant data readout in the first half of 2027. Taken together, these clinical, financial, and valuation considerations underpin his decision to rate the stock as a Buy.
According to TipRanks, Stringer is a 5-star analyst with an average return of 23.4% and a 47.67% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Ionis Pharmaceuticals.